

Table 1. Relative Lipid-lowering Effects Of The Available Statins In Primary Hypercholesterolemia And Mixed Dyslipidemia¹⁻³²

	Atorvastatin	Fluvastatin	Lovastatin	Pravastatin	Rosuvastatin	Simvastatin	Ezetimibe/Simvastatin
Labeled Dosage Range	10 mg to 80 mg once daily	20 mg to 80 mg daily	10 mg to 80 mg/day given 1-2 times daily	10 mg to 80 mg once daily	5 mg to 40 mg once daily	5 mg to 80 mg once daily	10/10 mg to 10/80 mg once daily
Effects on Lipids at Recommended Doses:							
Decrease in LDL	39% to 60%	22% to 35%	21% to 42%	22% to 37%	45% to 63%	26% to 47%	46% to 60%
Decrease in TC	29% to 45%	17% to 27%	16% to 34%	16% to 27%	33% to 46%	19% to 36%	15% to 43%
Decrease in ApoB	32% to 50%	18% to 28%	NR	NR	38% to 54%	NR	NR
Decrease in TG	19% to 37%	12% to 19%	6% to 27%	11% to 24%	10% to 35%	12% to 33%	8% to 28%
Increase in HDL	5% to 9%	3% to 7%	2% to 13%	2% to 12%	8% to 14%	8% to 16%	1.8% to 12.3%
Equivalent Daily Dose to lower LDL 30 – 40%	10 mg	80 mg	40 mg	40 mg	2.5 – 5 mg	20 – 40 mg	10/10 mg

Abbreviations: ApoB = apolipoprotein B; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; NR = not reported; TC = total cholesterol; TG = triglycerides

Table 2. Lipid-Altering Effects Of The Statins And Ezetimibe/Simvastatin In Comparative Clinical Trials^{3, 4, 14-19, 22, 23, 25, 27-84}

Agent	Daily Dose (mg)	Percent (%) Change from Baseline			Number of Included Studies*
		Mean Decrease LDL	Mean Increase HDL	Median Decrease TG	
Atorvastatin	5	27	21	2	16
	10	29 to 40	24 to 30	1 to 10	5 to 23
	20	33 to 46	27 to 35	4 to 10	14 to 26
	40	27 to 51	17 to 41	0 to 11	21 to 42
	80	43 to 54	38 to 48	-2 to +5	25 to 39
Fluvastatin	20	9 to 19	12 to 13	1 to 8	3 to 9
	40	19 to 33	17 to 27	-3 to +30	4 to 31
	80	22	20	5	2
Lovastatin	10	22	15	5	6
	20	17 to 29	19 to 21	4 to 9	6 to 16
	40	28 to 32	20 to 23	5 to 8	2 to 11
	80	25 to 48	22 to 36	-6 to +19	13 to 25
Pravastatin	10	17 to 28	11 to 18	3 to 17	+3 to -8
	20	22 to 32	3 to 24	3 to 8	2 to 24
	40	26 to 34	18 to 27	6 to 16	+3 to -16
Rosuvastatin	5	39 to 46	28 to 32	6 to 13	12 to 23
	10	41 to 50	30 to 35	4 to 12	12 to 22
	20	52	37 to 38	7 to 10	18 to 24
	40	55 to 57	40 to 41	10 to 12	26
	80	58 to 62	45 to 46	10 to 12	20 to 28
Simvastatin	5	21 to 31	16 to 23	8	8 to 13
	10	27 to 36	17 to 27	1 to 11	0 to 18
	20	18 to 38	17 to 28	3 to 12	2 to 22
	40	23 to 43	14 to 34	2 to 10	11 to 23
	80	43 to 49	33 to 40	6 to 17	18 to 27
Ezetimibe/Simvastatin	10/10	46 to 47	34	8	46
	10/20	33 to 53	20 to 36	2 to 10	8.4 to 50
	10/40	57 to 59	---	9	---
	10/80	59	43	12	35

* Studies were included only if they reported results for individual statin doses. Studies that reported results for a mean statin dosage after dose titration were not included.

Prepared by: Erin R. Fox, PharmD, Drug Information Specialist
Edited by: Linda S. Tyler, PharmD, Director, Drug Information Service
Date: June 8, 2007
©2007 University of Utah, Drug Information Services, Salt Lake City, UT.

References

1. Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. *Ann Pharmacother* 2004;38(7-8):1286-92.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004;110(2):227-39.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003;326(7404):1423.
4. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. *BMC Fam Pract* 2003;4:18.
5. Andrx Laboratories. Altorev (lovastatin) extended-release tablets package insert. In. Weston, FL: Andrx Laboratories, Inc.; May 2004.
6. Bristol-Myers Squibb. Pravachol (pravastatin sodium) tablets package insert. In. Princeton, NJ: Bristol-Myers Squibb Company; December 2004.
7. Merck. Mevacor (lovastatin) tablets package insert. In. Whitehouse Station, NJ: Merck & Co., Inc.; April 2005.
8. Merck. Zocor (simvastatin) tablets package insert. In. Whitehouse Station, NJ: Merck & Co., Inc.; November 2004.
9. Zocor 80 mg tablet, new indication cleared; Lipitor expands indications. F-D-C Reports - "The Pink Sheet" 1998;July 20:11.
10. Lea AP, McTavish D. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. *Drugs* 1997;53(5):828-47.
11. AstraZeneca. Crestor (rosuvastatin calcium) tablets package insert. In. Wilmington, DE: AstraZeneca Pharmaceuticals; January 2005.
12. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. *Am J Cardiol* 2001;88(5):504-8.
13. Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. *Am Heart J* 2003;145(6):1036-45.
14. Ballantyne CM, Blazing MA, Hunninghake DB, et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). *Am Heart J* 2003;146(5):862-9.
15. Davidson MH, Palmisano J, Wilson H, Liss C, Dicklin MR. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. *Clin Ther* 2003;25(11):2738-53.
16. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. *Int J Clin Pract* 1999;53(8):609-11.
17. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. *Am J Cardiol* 2003;92(11):1287-93.
18. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. *J Am Coll Cardiol* 2002;40(12):2125-34.
19. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc* 2004;79(5):620-9.
20. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. *Clin Ther* 2004;26(11):1758-73.
21. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. *Atherosclerosis* 2005;179(2):361-7.
22. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. *Curr Med Res Opin* 2005;21(4):571-8.
23. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. *Int J Cardiol* 2005;102(2):327-32.
24. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. *Am J Kidney Dis* 2006;47(3):385-95.
25. Masana L, Mata P, Gagne C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. *Clin Ther* 2005;27(2):174-84.
26. Gaudiani LM, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in

- thiazolidinedione-treated type 2 diabetic patients. *Diabetes Obes Metab* 2005;7(1):88-97.
27. Feldman T, Koren M, Insull W, Jr., et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. *Am J Cardiol* 2004;93(12):1481-6.
28. Rodney RA, Sugimoto D, Wagman B, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. *J Natl Med Assoc* 2006;98(5):772-8.
29. Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. *Int J Clin Pract* 2005;59(12):1377-86.
30. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. *Am Heart J* 2005;149(3):464-73.
31. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. *Am J Cardiol* 2004;93(12):1487-94.
32. McKenney J, Ballantyne CM, Feldman TA, et al. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. *MedGenMed* 2005;7(3):3.
33. Parke-Davis. Data on file, Protocol 981-86. In. Morris Plains, NJ; 1996.
34. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). *Am J Cardiol* 1998;81(5):582-7.
35. Branchi A, Fiorenza AM, Rovellini A, et al. Lowering effects of four different statins on serum triglyceride level. *Eur J Clin Pharmacol* 1999;55(7):499-502.
36. Wolffenbuttel BH, Mahla G, Muller D, Pentrup A, Black DM. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. *Neth J Med* 1998;52(4):131-7.
37. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R, for the CHALLENGE Study Investigators. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. *Am J Cardiol* 2002;89(6):667-71.
38. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. *Am J Cardiol* 2001;87(5):554-9.
39. Crouse JR, 3rd, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. *Am J Cardiol* 1999;83(10):1476-7.
40. Illingworth DR, Crouse JR, 3rd, Hunninghake DB, et al, for the Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. *Curr Med Res Opin* 2001;17(1):43-50.
41. Kastelein JJP, Isaacsohn JL, Ose L, et al, for the Simvastatin Atorvastatin HDL Study Group. Comparison of the effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1 levels. *Am J Cardiol* 2000;86:221-3.
42. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. *J Cardiovasc Pharmacol Ther* 2000;5(1):27-32.
43. Recto CS, 2nd, Acosta S, Dobs A. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. *Clin Cardiol* 2000;23(9):682-8.
44. Calder RA. Comparison of Zocor and atorvastatin [written communication, July 17, 2002]. In. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
45. Branchi A, Fiorenza AM, Torri A, et al. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. *Clin Ther* 2001;23(6):851-7.
46. Berger ML, Wilson HM, Liss CL. A Comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia. *J Cardiovasc Pharmacol Ther* 1996;1(2):101-6.
47. Nash D. Meeting national cholesterol education goals in clinical practice - A comparison of lovastatin and fluvastatin in primary prevention. *Am J Cardiol* 1996;78 (Suppl 6A):26-31.
48. Jacotot B, Benghozi R, Pfister P, et al, for the French Fluvastatin Study Group. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. *Am J Cardiol* 1995;76:54A-6A.
49. Milani M, Cimmino C, Merlo B, Lorena M, Arpaia G, Bonfardeci G. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. *Am J Cardiol* 1995;76(2):51A-3A.
50. van Dam MJ, Penn HJ, den Hartog FR, et al, for the MUST Study Group. A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. *Clin Ther* 2001;23(3):467-78.
51. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. *J Cardiovasc Pharmacol Ther* 1996;1(1):23-30.
52. Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. *Am J Cardiol* 1993;71(10):810-5.
53. Weir AR, Berger ML, Weeks ML, et al, for the Quality of Life Multicenter Group. Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin. *Am J Cardiol* 1996;77:475-9.

54. McPherson R, Bedard J, Connelly P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. *Clin Ther* 1992;14(2):276-91.
55. Richter WO, Jacob BG, Schwandt P. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins. *Int J Tiss Reac* 1991;2:107-10.
56. Farmer JA, Washington LC, Jones PH, et al, for the Simvastatin and Lovastatin Multicenter Study. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. *Clin Ther* 1992;14(5):708-17.
57. Seed M, Weir MR, for the International Quality of Life Multicenter Group. Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group. *Clin Ther* 1999;21(10):1758-70.
58. European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). *Am J Cardiol* 1992;70(15):1281-6.
59. Steinhagen-Thissen E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group. *Cardiology* 1994;85(3-4):244-54.
60. Lambrecht LJ, Malini PL, European Study Group. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group. *Acta Cardiol* 1993;48(6):541-54.
61. Malini PL, Ambrosioni E, De Divitiis O, Di Somma S, Rosiello G, Trimarco B. Simvastatin versus pravastatin: Efficacy and tolerability in patients with primary hypercholesterolemia. *Clin Ther* 1991;13(4):500-10.
62. Yoshino G, Kazumi T, Matsushita M, et al. Comparison of the effects of pravastatin and simvastatin in hypercholesterolemic subjects. *Curr Ther Res* 1990;48(2).
63. Stalenhoef AF, Lansberg PJ, Kroon AA, et al. Treatment of primary hypercholesterolemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study. *J Intern Med* 1993;234(1):77-82.
64. Sasaki S, Sawada S, Nakata T, et al. Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia. *J Cardiovasc Pharmacol* 1997;30(1):142-7.
65. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. *Am J Cardiol* 2003;91(1):33-41.
66. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. *Am Heart J* 2002;144(6):1044-51.
67. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. *Am J Cardiol* 2002;89(3):268-75.
68. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. *Atherosclerosis* 2002;164(2):361-9.
69. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. *Am Heart J* 2002;144(6):1036-43.
70. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. *J Cardiovasc Risk* 2001;8(6):383-90.
71. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). *Am J Cardiol* 2003;92(2):152-60.
72. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. *Am Heart J* 2004;147(4):705-13.
73. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blaseth JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. *Am J Cardiol* 2005;95(3):360-6.
74. Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. *Am Heart J* 2006;151(5):975 e1-9.
75. Sirtori CR, Calabresi L, Pisciotta L, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. *Nutr Metab Cardiovasc Dis* 2005;15(1):47-55.
76. Saklamaz A, Comlekci A, Temiz A, et al. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. *Metabolism* 2005;54(5):677-81.
77. Fonseca FA, Ruiz A, Cardona-Munoz EG, Silva JM, Fuenmayor N, Marotti M. The DISCOVERY PENTA study: a DIrect Statin COMparison of LDL-C Value--an Evaluation of Rosuvastatin therapy compared with atorvastatin. *Curr Med Res Opin* 2005;21(8):1307-15.
78. Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. *Clin Ther* 2004;26(11):1821-33.
79. Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. *Am Heart J* 2004;148(1):e4.
80. Marketou ME, Zacharis EA, Nikitovic D, et al. Early effects of simvastatin versus atorvastatin on oxidative stress and

- proinflammatory cytokines in hyperlipidemic subjects. *Angiology* 2006;57(2):211-8.
81. Paragh G, Torocsik D, Seres I, et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinemia. *Curr Med Res Opin* 2004;20(8):1321-7.
82. Mauger JF, Couture P, Paradis ME, Lamarche B. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. *Atherosclerosis* 2005;178(1):157-63.
83. Zhang B, Noda K, Matsunaga A, Kumagai K, Saku K. A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia. *J Atheroscler Thromb* 2005;12(1):41-7.
84. Gagne C, Bays H, Weiss S, et al. Efficacy and Safety of Ezetimibe Added to Ongoing Statin Therapy for Treatment of Patients With Primary Hypercholesterolemia. *Am J Cardiol* 2002;90:1084-91.